ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Up 323.2% in March

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 187,900 shares, an increase of 323.2% from the February 28th total of 44,400 shares. Currently, 7.5% of the company’s stock are short sold. Based on an average trading volume of 830,400 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Virtu Financial LLC bought a new stake in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 1.08% of ZyVersa Therapeutics at the end of the most recent quarter. Institutional investors own 3.91% of the company’s stock.

ZyVersa Therapeutics Trading Down 5.4 %

Shares of ZyVersa Therapeutics stock opened at $0.70 on Friday. ZyVersa Therapeutics has a 1 year low of $0.65 and a 1 year high of $8.40. The firm’s 50-day moving average is $1.12 and its 200 day moving average is $1.47.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.